ILiAD Biotechnologies Announces Planned Collaboration with Emmes Group, a New Mountain Capital Portfolio Company, to Conduct Upcoming Phase III Clinical Trials of BPZE1, the Leading Next-Generation Pertussis Vaccine
ILiAD Biotechnologies, LLC
生物技术研究
Weston，Florida 914 位关注者
ILiAD is advancing the next generation pertussis vaccine for the prevention of whooping cough.
关于我们
ILiAD Biotechnologies is utilizing its B-Tech vector platform to develop next generation vaccines to eradicate infectious diseases and improve lives. Its lead candidate, BPZE1, which has completed Phase 2 clinical trials, is the most advanced next generation vaccine for the prevention of whooping cough, a serious illness caused by Bordetella pertussis.
- 网站
-
https://www.iliadbio.com
ILiAD Biotechnologies, LLC的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- Weston，Florida
- 类型
- 私人持股
- 创立
- 2012
- 领域
- Infectious Diseases和Pediatrics
地点
-
主要
获取路线
4581 Weston Road
Suite 260
US，Florida，Weston，33331
ILiAD Biotechnologies, LLC员工
动态
-
ILiAD Biotechnologies will be participating in the following investor conferences: ·?4th Annual Needham Private Biotech Company Virtual 1x1 Forum, October 8-9, 2024 · Leerink Partners Biopharma Private Company Connect, October 22-23, 2024 ILiAD management will be hosting virtual 1x1 investor meetings during the conferences.?
-
The New York Stock Exchange's Healthcare and Life Sciences Capital Markets team celebrated our Fierce 15 Award with a special event on the NYSE Trading Floor. Thank you! NYSE Fierce Biotech
-
-
Fierce Biotech Names ILiAD Biotechnologies to its 2024 Fierce 15 https://lnkd.in/eXVdVv4z
-
-
ILiAD Biotechnologies Reports Positive Topline Interim Results from Phase 2b School-Age Trial of BPZE1 Pertussis Vaccine
ILiAD Biotechnologies Reports Positive Topline Interim Results from Phase 2b School-Age Trial of BPZE1 Pertussis Vaccine
businesswire.com